Gentronix Ltd.
Gentronix was founded in 1999 as a spin-out from The University of Manchester to commercialise patented new technology for the early identification of genotoxic carcinogens. This technology is now available in a kit format, known as GreenScreen HC, for the early genotoxicity screening of new drug compounds.
Developed in a simple microplate format requiring less than 1mg of compound, the assay is easily automated using standard laboratory equipment. Published results and trial data demonstrate a unique combination of exceptionally high sensitivity and specificity, making GreenScreen HC the first in vitro mammalian cell assay truly suitable for early candidate screening.
Reviews
No reviews to display
Latest Videos
Latest news
News
GSK Validates High Throughput Format of Gentonix Bluescreen® Assay
24 Apr 2013
-
Early detection of Genotoxicity: Integrated Services from Gentronix
25 Aug 2011
-
Gentronix Further Expands Early Genotoxicity Screening Capability with Introduction of Ames MPF™ Screening Service
30 Mar 2011
-
ADVANCELL partners with Gentronix to Offer Genotoxicity Screening Assays to the Cosmetics and Personal Care Sector
09 Dec 2010
-
Gentronix Blue Screen HC Genotoxicity Screening Test Now Available from Charles Rivers Laboratories
21 Sep 2010
